On Monday, LeMaitre Vascular got a positive adjustment to its Relative Strength (RS) Rating, from 65 to 73.
IBD's proprietary RS Rating tracks technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the top-performing stocks typically have an RS Rating of over 80 as they launch their biggest price moves. See if LeMaitre Vascular can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
While it's not currently an ideal time to jump in, see if the stock goes on to offer and clear a proper buy point.
The company reported 29% EPS growth last quarter. Sales gains came in at 14%. The next quarterly numbers are expected on or around May 1.
The company holds the No. 12 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
